Skip to main content
Mayinglong Pharmaceutical Group Co.,Ltd logo

Mayinglong Pharmaceutical Group Co.,Ltd — Investor Relations & Filings

Ticker · 600993 ISIN · CNE000001HN2 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 931 across all filing types
Latest filing 2013-04-24 Interim / Quarterly Rep…
Country CN China
Listing Shanghai Stock Exchange 600993

About Mayinglong Pharmaceutical Group Co.,Ltd

https://www.mayinglong.cn/

Mayinglong Pharmaceutical Group Co.,Ltd. is a long-established enterprise specializing in the research, development, and production of Traditional Chinese Medicine (TCM). Founded in 1582, the company is widely recognized for its expertise in proctology, maintaining a dominant market position with its signature hemorrhoid ointments and suppositories. Its product portfolio also includes ophthalmic preparations, dermatological treatments, and gastrointestinal medicines. The company integrates traditional medicinal formulas with modern manufacturing technologies to provide healthcare solutions. Beyond pharmaceuticals, Mayinglong has expanded into healthcare services, including specialized hospitals and personal care products, focusing on the integration of clinical treatment and health management.

Recent filings

Filing Released Lang Actions
2013年第一季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled '2013 年第1 季度报告' which translates to '2013 First Quarter Report'. It contains detailed financial data including balance sheets, profit and loss statements, cash flow statements, and management commentary for the first quarter of 2013. The report is unaudited as stated in the text. The length of the document is about 15,000 characters, indicating it is a full report rather than a brief announcement. The content includes comprehensive financial statements and analysis for a period shorter than a full fiscal year, consistent with an Interim / Quarterly Report. There is no indication that this is an annual report, audit report, or other filing types. Therefore, the document is best classified as an Interim / Quarterly Report (IR). Q1 2013
2013-04-24 Chinese
2012年年度报告摘要
Annual Report Classification · 95% confidence The document is titled as "2012 年年度报告摘要" which translates to "2012 Annual Report Summary". It contains detailed financial data for the year 2012, including main financial data, shareholder changes, management discussion and analysis, business segment performance, asset and liability analysis, investment status, and future development discussion. The length is about 15,000 characters, indicating a substantive report rather than a brief announcement. The content includes comprehensive financial statements and management analysis typical of an annual report. Therefore, this document is best classified as an Annual Report (10-K equivalent). FY 2012
2013-04-24 Chinese
第七届董事会第十五次会议决议公告
Board/Management Information Classification · 100% confidence The document is a formal announcement from the board of directors of 马应龙药业集团股份有限公司 regarding a change in senior management, specifically the resignation of the vice general manager due to work changes. It is titled as a board meeting resolution announcement and contains no financial data or report content. This fits the category of Board/Management Information (MANG). The document length is short and focused solely on management changes, confirming the classification.
2012-12-28 Chinese
股改限售流通股上市公告
Regulatory Filings Classification · 95% confidence The document is titled as a "股改限售流通股上市公告" which translates to "Announcement of Listing of Restricted Circulating Shares from Share Reform". It details the number of shares being listed, dates of listing, changes in shareholding structure, shareholder commitments, and historical shareholding changes. It includes specific data on share quantities, shareholder names, and compliance with share reform commitments. The document is an official announcement regarding the listing of restricted shares following a share reform process, not a financial report, earnings release, or management discussion. It is not a full annual or interim report, nor a proxy or voting result announcement. The content is regulatory in nature, providing detailed disclosure about share listing and shareholder changes. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2012-12-21 Chinese
：长江证券承销保荐有限公司关于马应龙药业集团股份有限公司有限售条件的流通股上市流通申请的核查意见书
Capital/Financing Update Classification · 95% confidence The document is a detailed verification opinion letter from Changjiang Securities Underwriting and Sponsorship Co., Ltd. regarding the application for listing and circulation of restricted circulating shares of Mayinglong Pharmaceutical Group Co., Ltd. It extensively discusses the company's equity reform plan, shareholder commitments, shareholding changes, and the listing of restricted shares. The content focuses on the regulatory compliance and approval process for the listing of restricted shares, including detailed shareholding data and historical changes. There is no indication that this is a full annual or interim financial report, earnings release, or management discussion. It is not a simple announcement but a formal verification opinion related to a specific capital market transaction concerning share listing and circulation. This fits the category of a Capital/Financing Update (CAP), as it relates to changes in capital structure and share listing approvals.
2012-12-21 Chinese
：广发证券股份有限公司关于马应龙药业集团股份有限公司有限售条件的流通股上市流通申请的核查意见书
Regulatory Filings Classification · 95% confidence The document is a detailed verification opinion letter from a sponsoring institution (广发证券股份有限公司) regarding the application for listing and circulation of restricted tradable shares of 马应龙药业集团股份有限公司. It includes extensive historical data on shareholding changes, stock reform implementation, shareholder commitments, and stock distribution details. The document is not a financial report like an annual or interim report, nor is it an earnings release or a call transcript. It is not a simple announcement but a comprehensive verification and opinion report related to share listing and compliance with stock reform regulations. This type of document fits best under Regulatory Filings (RNS) as it is a regulatory compliance and verification filing that does not fit other specific categories such as capital updates or management changes.
2012-12-21 Chinese

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.